U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07034768) titled 'A Study to Evaluate EDG-7500 in People With Renal Impairment' on June 09.
Brief Summary: The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Renal Impairments
Intervention:
DRUG: EDG-7500
Single dose of EDG-7500
Recruitment Status: RECRUITING
Sponsor:...